Bristol-Myers Squibb Company Reports Fourth Quarter and Full Year 2012 Financial Results

Published: Jan 24, 2013

Bristol-Myers Squibb Company (NYSE: BMY) today announced results for the fourth quarter of 2012 highlighted by regulatory approvals for Eliquis®and Forxiga®. This concluded a year in which the Company delivered growth of its key products as it transitioned to its promising future portfolio. In addition, the company provided financial guidance for 2013.

Back to news